Table 1 Demographic, clinical, radiological, and pathological characteristics of the study cohort
Characteristics | Number or as shown | Proportion (%) |
|---|---|---|
All | 93 | 100 |
Gender | ||
 Male | 56 | 60.2 |
 Female | 37 | 39.8 |
Age [median (range)], months | 11 (1.7–87) | – |
AFP level [median (range)], ng/ml | 76,131 (10–1,881,360) | – |
Maximum tumour diameter [median (range)], cm | 10.6 (5.1–15.8) | – |
Focality | ||
 Unifocal | 57 | 61.3 |
 Multifocal | 7 | 7.5 |
 Unknown | 29 | 31.2 |
PRETEXT stage | ||
 I | 0 | 0.0 |
 II | 36 | 38.7 |
 III | 23 | 24.7 |
 IV | 3 | 3.2 |
 Unknown | 31 | 33.3 |
Rupture | ||
 Yes | 7 | 7.5 |
 No | 56 | 60.2 |
 Unknown | 30 | 32.3 |
Metastasis | ||
 Yes | 9 | 9.7 |
 No | 55 | 59.1 |
 Unknown | 29 | 31.2 |
Portal vein thrombosis | ||
 Yes | 1 | 1.1 |
 No | 63 | 67.7 |
 Unknown | 29 | 31.2 |
Hepatic vein thrombosis | ||
 Yes | 0 | 0.0 |
 No | 64 | 68.8 |
 Unknown | 29 | 31.2 |
Primary resection | ||
 Yes | 16 | 17.2 |
 No | 77 | 82.8 |
Neoadjuvant chemotherapy | ||
 Yes [n, median (range)] | 52, 2.5 (1–8) | 55.9 |
 No | 41 | 44.1 |
Preoperative TACE, cycles | ||
 Yes [n, median (range)] | 55, 2 (1–7) | 59.1 |
 No | 38 | 40.9 |
POSTTEXTa stage (n = 77) | ||
 I | 4 | 5.2 |
 II | 36 | 46.8 |
 III | 9 | 11.7 |
 IV | 1 | 1.3 |
 Unknown | 27 | 35.1 |